CHRS Q1 2025 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+229.2% YoY

Gross Profit

$5M65.1% margin

Operating Income

-$45M-597.9% margin

Net Income

-$57M-744.4% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-86.0%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$371M

Total Liabilities

$555M

Stockholders' Equity

-$183M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$2M	+229.2%
Gross Profit	$5M	$869,000	+469.2%
Operating Income	-$45M	-$68M	+33.0%
Net Income	-$57M	$103M	-155.0%

Revenue Segments

Product and Service, Other

$251,000100%